Icure Pharmaceutical Incorporation reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported negative sales was KRW 669.6 million compared to sales of KRW 132.4 million a year ago. Net loss was KRW 5,537.78 million compared to KRW 9,442.39 million a year ago. Basic loss per share from continuing operations was KRW 147 compared to KRW 415 a year ago. Diluted loss per share from continuing operations was KRW 147 compared to KRW 415 a year ago. Basic loss per share was KRW 147 compared to KRW 498 a year ago.
For the six months, sales was KRW 1,124.89 million compared to KRW 305.16 million a year ago. Net loss was KRW 12,685.18 million compared to KRW 16,316.19 million a year ago. Basic loss per share from continuing operations was KRW 338 compared to KRW 717.5 a year ago. Diluted loss per share from continuing operations was KRW 338 compared to KRW 717.5 a year ago. Basic loss per share was KRW 338 compared to KRW 861 a year ago.